Is neuroglial antigen 2 a potential contributor to cilengitide response in glioblastoma?

Nalkiran H., MCDONALD K. L.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.13, sa.2, ss.329-336, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4103/0973-1482.188438
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.329-336
  • Anahtar Kelimeler: Apoptosis, cell detachment, dose-response relationship, drug resistance, gene expression, PHASE-II TRIAL, NEWLY-DIAGNOSED GLIOBLASTOMA, RECURRENT MALIGNANT GLIOMAS, NG2 PROTEOGLYCAN, ENDOTHELIAL-CELLS, TEMOZOLOMIDE, BEVACIZUMAB, PHOSPHORYLATION, ALPHA-V-BETA-3, ACTIVATION
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Evet

Özet

Background: Determining the expression levels of neuroglial antigen 2 (NG2) in glioma cell lines and to evaluate the potential contribution of NG2 to cilengitide response were aimed.